Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein conjugate; Prevenar™) in Korean infants: Differences that are found in Asian children

Nam Hee Kim, Jina Lee, Sang Jeong Lee, Hyunju Lee, Kyung Hyo Kim, Su Eun Park, Hoan Jong Lee

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

This study was conducted to determine the immunogenicity and safety of a 7-valent CRM197 protein conjugated pneumococcal vaccine (PCV7) in Korean infants immunized at 2, 4 and 6 months. A total of 202 infants were enrolled and 146 and 141 infants were, respectively, included in post-2nd dose and post-3rd dose immunogenicity evaluations conducted on a per protocol basis. After two and three PCV7 vaccinations, 63.0-98.0 and 97.2-100% of infants achieved an antibody level of ≥0.35 μg/mL, respectively, with a lowest against serotype 6B. No vaccination-related serious adverse reactions were observed. Thus, PCV7 appears safe and highly immunogenic in Korean infants, and adopting two doses for a primary series could be a feasible option for facilitating vaccine coverage rate.

Original languageEnglish
Pages (from-to)7858-7865
Number of pages8
JournalVaccine
Volume25
Issue number45
DOIs
StatePublished - 7 Nov 2007

Bibliographical note

Funding Information:
This work was supported by the Seoul National University Hospital (#06-04-126) which was underwritten by Wyeth Research.

Keywords

  • Ethnic groups
  • Pneumococcal conjugate vaccine
  • Reduced dose vaccination

Fingerprint

Dive into the research topics of 'Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein conjugate; Prevenar™) in Korean infants: Differences that are found in Asian children'. Together they form a unique fingerprint.

Cite this